Drug Designing: Open Access
265 views | +0 today
Follow
Drug Designing: Open Access
“Drug Designing: Open Access is an international, peer-reviewed journal publishing an overview of drug design”
Curated by drug designing
Your new post is loading...
Your new post is loading...
Scooped by drug designing
Scoop.it!

Drug Designing: Open Access

Drug Designing: Open Access | Drug Designing: Open Access | Scoop.it

Drug Designing is an Open Access, peer-reviewed journal which aims to provide the most rapid and reliable source of information on current developments in the field of Drug Designing.Drug Designing: Open Access is using online manuscript submission, review and tracking systems for quality and quick review processing.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Express Pharma November reveals about Dr Srinubabu Gedela, Director, OMICS Group

Criteria of speaker selection is important to convey the quality level

Initiation of cross-border co-operations between scientists and institutions is facilitated at the conference. This is an excellent opportunity for delegates from universities and institutions to interact with leading industry experts and debate on the latest regulatory updates..

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Drug Designing: Open Access- Submit Manuscript

Drug Designing: Open Access- Submit Manuscript | Drug Designing: Open Access | Scoop.it

OMICS Group is using an online submission and review system. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process. Publishers can see what manuscripts are in the pipeline.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Collagen shapes a new path for Drugs

Collagen shapes a new path for Drugs | Drug Designing: Open Access | Scoop.it

Collagen binds other proteins that have interesting functions. Cells come along and bind to those proteins attached to collagen. Based on this interaction, a cell will then decide how to behave or differentiate into a different type of cell. This property makes collagen especially valuable forbiological scaffolds, materials that are under intense study as a way to grow new body parts and even entire organs to replace damaged ones.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Sensitive Quantitative Predictions of mhc Binding Peptides and Fragment Based Peptide Vaccines From Trichinella spiralis

Sensitive Quantitative Predictions of mhc Binding Peptides and Fragment Based Peptide Vaccines From Trichinella spiralis | Drug Designing: Open Access | Scoop.it

Trichinella spiralis is a nematode parasite, occurring in rats, pigs, bears and humans, and is responsible for the disease trichinosis. Peptide fragments of antigen protein can be used to select nonamers for use in rational vaccine design and to increase the understanding of roles of the immune system in infectious diseases. Analysis shows MHC class II binding peptides of antigen protein from Trichinella spiralis are important determinant for protection of host form parasitic infection

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Flexible, Adaptive or Attractive Clinical Trial Design

Flexible, Adaptive or Attractive Clinical Trial Design | Drug Designing: Open Access | Scoop.it

In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular due to its flexibility and efficiency for identifying clinical benefit of the test drug or therapy under investigation. The use of adaptive design methods in clinical trials is motivated by the Critical Path Initiative by the United States Food and Drug Administration (FDA) in early 2000.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Data Mining Methods for ‘OMICs’ Applications in Anticancer Drug Design and Discovery

Data Mining Methods for ‘OMICs’ Applications in Anticancer Drug Design and Discovery | Drug Designing: Open Access | Scoop.it

 Data mining methodology as one of cheminformatics tools is applicable in drug discovery process to analyze related data from many different sources, classifying and summarizing the relationships identified. The high throughput data collectively referred to as ‘OMICs’ data are ubiquitous during the drug design and discovery process from target identification and validation to the development and testing of novel anticancer drug candidates to solving cancer treatment challenges.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Jeffrey Beall is blackmailing small Open Access publishers through his predatory publishers blog

drug designing's insight:

I was surprised when one of our editors told me that the name of Ashdin Publishing is found in the list of "Beall's List: Potential, possible, or probable predatory scholarly open-access publishers" (http://scholarlyoa.com/publishers/) and I was surprised because of the following reasons:

The author did not just mention the criteria for determining predatory open-access publishers, but he insisted on mentioning the full names and details of the publishers as well.Some of these criteria, for determining predatory open-access publishers, can be applied on a huge number of publishers (include some of the large and famous ones), but he did not mention any of them.Some of the publishers names are removed from this list without saying the reasons for this removal.

After I received the e-mail below, I am not any more surprised. Now, I am sure that the author, irrespective the good reasons he may has for preparing this list, wants to blackmail small publishers to pay him. 


I invite all of you to read what people say commenting on his article (http://www.nature.com/news/predatory-publishers-are-corrupting-open-access-1.11385)Nature is removed and constantly removing the negative posts against Beals article. http://www.nature.com/news/report?article=1.11385&comment=52626 ;

Dr Gillian Dooley (Special Collections Librarian at Flinders University):

Jeffrey Beall's list is not accurate to believe. There are a lot of personal biases of Jeffrey Beall. Hindawi still uses heavy spam emailing. Versita Open still uses heavy spam emailing. But these two publishers have been removed in Jeffrey Beall's list recently. There is no reason given by Jeffrey Beall why they were removed. Jeffrey Beall is naive in his analysis. I think some other reliable blog should be created to discuss more fruitfully these issues. His blog has become useless.

Mark Robinson (Acting Editor, Stanford Magazine):

It is a real shame that Jeffrey Beall using Nature.com's blog to promote his predatory work. Jeffrey Beall just simply confusing us to promote his academic terrorism. His list is fully questionable. His surveying method is not scientific. If he is a real scientist then he must do everything in standard way without any dispute. He wanted to be famous but he does not have the right to destroy any company name or brand without proper allegation. If we support Jeffrey Beall's work then we are also a part of his criminal activity. Please avoid Jeffrey Beall's fraudulent and criminal activity.

Now a days anyone can open a blog and start doing things like Jeffrey Beall which is harmful for science and open access journals. Nature should also be very alert from Jeffrey Beall who is now using Nature's reputation to broadcast his bribery and unethical business model.

Now, I invite all of you in order to take all precautions and not being misled by this blackmailer.

Ashry A. Aly
Director
Ashdin Publishing
http://www.ashdin.com
more...
No comment yet.
Scooped by drug designing
Scoop.it!

Dr Srinubabu Gedela, Director, OMICS Group of Conferences, reveals more toSachin Jagdale about pharma conferences and their plans for the Indian pharma industry

Dr Srinubabu Gedela, Director, OMICS Group of Conferences, reveals more toSachin Jagdale about pharma conferences and their plans for the Indian pharma industry | Drug Designing: Open Access | Scoop.it

What are the future plans of OMICS for the Indian pharma industry?

Research in science is important, as it leads to ‘progress’ in education, which further leads to ‘progress in science’ and ultimately accelerating scientific discoveries and technological innovations. Scientists, researchers, academicians, innovators, industry professionals, scholars and students are constantly in need of information that will benefit their research. OMICS Group Conferences and OMICS Publishing Group provide an open-arena where cutting-edge research ideas and latest happenings in the fields of medicine and science especially pharma sciences are exhibited, which in turn foster new research directions and approaches.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Quantitative Prediction of MHC Binding Peptides Vaccines from Trichinella Spiralis

Quantitative Prediction of MHC Binding Peptides Vaccines from Trichinella Spiralis | Drug Designing: Open Access | Scoop.it

Trichinella species are the smallest nematode parasite of humans, having an unusual life cycle. It occurs in rats, pigs, bears and humans, & is responsible for the disease trichinosis. They are one of the most widespread and clinically important parasites in the world antigen peptides & are most suitable for subunit vaccine development because with single epitope, the immune response can be generated in large population.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Drug Resistant Malaria in Asia

Drug Resistant Malaria in Asia | Drug Designing: Open Access | Scoop.it

In Asia and mainly South East Asia, drug resistant malaria is spreading at a high level. The drugs that are used worldwide to cure malaria are now a waste. Resistance to these has emerged in various parts like Thailand, and many more. Drug resistant malaria was initially found eight years ago at the borders of Thailand-Cambodia.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

Drug Discovery with Novel Chemical Libraries

Drug Discovery with Novel Chemical Libraries | Drug Designing: Open Access | Scoop.it

Several drug discovery and design endevours are focused on an exhaustive exploration of the drug-like chemical space with the final goal of identifying compounds that can be developed clinically. The traditional drug-like chemical space has been defined using old drugs with empirical rules such as the Lipinski’s Rule-of-Five (RO5). Therefore, promising drug candidates may be overlooked because they are outside the boundaries of currently aproved drugs.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

The Future of Prodrugs Designed by Computational Chemistry

The Future of Prodrugs Designed by Computational Chemistry | Drug Designing: Open Access | Scoop.it

The modern approach to be discussed in this editorial implies the design of prodrugs based on intramolecular processes utilizing molecular orbital methods and correlations between experimental and calculated values. No enzyme is needed for the catalysis of the conversion of a prodrug to the corresponding drug. The rate of drug release is dependent only on the rate limiting step for the conversion of its corresponding prodrug. Knowledge gained from enzyme catalysis and intramolecularity was used in the design.

more...
No comment yet.
Scooped by drug designing
Scoop.it!

The Multi-Target Drug Design Era is Here, Consider it

The Multi-Target Drug Design Era is Here, Consider it | Drug Designing: Open Access | Scoop.it

The desire to develop more effective treatment agents for complex disease states (Alzheimer’s, Parkinson’s, diabetes, cancer, etc.) seems to be pushing drug design towards the multi-target approach. This shift in drug design is partly driven by the success of combination (multi-drug cocktail, multicomponent) chemotherapy utilized in cancer and HIV. Just how much drug design, in general, has shifted from the traditional mono-target to a pluralistic multi-target paradigm is still an open question.

more...
No comment yet.